Abstract
Combination therapy compares favorably with monotherapy with regard to clinical outcome and side effects. The dose of AZT and ddI used in combination therapy may approximate that of monotherapy without increasing the frequency of side effects. The children in Arm B had more advanced disease, and possibly had developed resistance to the AZT they had previously been prescribed. Arm B showed much less benefit from therapy than Arm A, both in immunologic parameters and survival.
- Copyright © 1995 by the American Academy of Pediatrics
Individual Login
Log in
You will be redirected to aap.org to login or to create your account.
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
ZIDOVUDINE AND DIDANOSINE COMBINATION THERAPY IN CHILDREN WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION
Jump to section
Related Articles
Cited By...
- No citing articles found.